Breast Cancer Stage IV Clinical Trial
Official title:
A Multicenter, Open-label, Randomized, Controlled, Prospective Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
This is a multicenter, open-label, randomized controlled, prospective clinical study to evaluate the efficacy and safety of Huaier Granules in patients with advanced breast cancer without visceral metastasis.
This study used a blank control design and included at least 384 subjects. The experimental group and control group were randomized in a 2:1 ratio (at least 256 subjects in the experimental group and at least 128 subjects in the control group). Patients in the experimental group were treated with Huaier Granules (10g/dose, 3 times/day), while undergoing routine diagnosis and treatment; The control group received routine diagnosis and treatment, but did not take Huaier granules until the subjects experienced disease progression or intolerance. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04469127 -
A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients.
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
| Terminated |
NCT04123704 -
Sitravatinib in Metastatic Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT05377047 -
Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
|
N/A | |
| Completed |
NCT03304210 -
PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
|
Phase 1 | |
| Completed |
NCT05054374 -
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05559528 -
BRaziLian outcomE for metAStatic breasT Cancer
|
||
| Active, not recruiting |
NCT05090358 -
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT05033925 -
Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03401359 -
The Resistance and Immune Response to Palbociclib in Breast Cancer
|
N/A | |
| Active, not recruiting |
NCT03870919 -
Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients
|
N/A | |
| Completed |
NCT00393341 -
Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer
|
N/A | |
| Recruiting |
NCT05625087 -
Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
|
Phase 2 | |
| Completed |
NCT04566458 -
RWD Study in HER2+ mBC Patients in Third-Line Therapy
|
||
| Recruiting |
NCT06075810 -
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04697043 -
The Benefit of Surgery in Stage IV of Breast Cancer
|
N/A | |
| Recruiting |
NCT05837533 -
Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients
|
N/A | |
| Active, not recruiting |
NCT03324425 -
Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT05670054 -
Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients
|
Phase 3 | |
| Terminated |
NCT03202446 -
Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer
|
Phase 3 |